Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Eur J Haematol
; 101(1): 95-105, 2018 Jul.
Article
in En
| MEDLINE
| ID: mdl-29660177
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Chronic-Phase
/
Gene Expression Regulation, Leukemic
/
Fusion Proteins, bcr-abl
/
Protein Kinase Inhibitors
/
Antineoplastic Agents
Type of study:
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eur J Haematol
Journal subject:
HEMATOLOGIA
Year:
2018
Document type:
Article
Affiliation country:
Country of publication: